Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $39.25 Average PT from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $39.25.

Several analysts have commented on STOK shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a research note on Monday, December 29th. HC Wainwright boosted their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 15th. Chardan Capital upped their price target on Stoke Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. Finally, UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research report on Monday, December 15th.

Insider Buying and Selling at Stoke Therapeutics

In other news, Director Adrian R. Krainer sold 33,243 shares of the firm’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total value of $1,321,076.82. Following the completion of the sale, the director owned 283,302 shares in the company, valued at approximately $11,258,421.48. This trade represents a 10.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Arthur Tzianabos sold 4,355 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $40.00, for a total transaction of $174,200.00. Following the completion of the sale, the insider directly owned 31,339 shares in the company, valued at approximately $1,253,560. The trade was a 12.20% decrease in their position. The SEC filing for this sale provides additional information. 9.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC acquired a new position in Stoke Therapeutics during the 4th quarter worth approximately $26,000. Harbour Investments Inc. lifted its holdings in shares of Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the period. Generali Investments Management Co LLC acquired a new stake in shares of Stoke Therapeutics in the 3rd quarter valued at approximately $41,000. BNP Paribas Financial Markets boosted its stake in shares of Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares in the last quarter.

Stoke Therapeutics Stock Down 9.0%

NASDAQ STOK opened at $33.19 on Friday. Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $40.22. The business’s 50-day moving average price is $32.71 and its 200 day moving average price is $29.56. The firm has a market cap of $1.90 billion, a P/E ratio of 49.54 and a beta of 1.07.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.